Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJia Yi TanDODaniel E. O’LearyTHTalal Hilal

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows CAR T-cell therapy lowers mortality and ICU use in relapsed multiple myeloma, suggesting clinical trials are needed for optimal treatment decisions.

Key Points

  • CAR T-cell therapy reduced all-cause mortality by 64% compared to bispecific antibodies, indicating significant efficacy in treatment outcomes.
  • Statistical analysis revealed that the mean age among patients was 66 years with 911 receiving CAR T-cell therapy and 1,112 receiving bispecific antibodies.
  • Observational analysis across health records identified risks of cytokine release syndrome and neutropenia were higher in the CAR T-cell group compared to the counterparts.
  • Further prospective clinical trials are essential to validate findings and optimize treatment decisions in this patient population.

Cite This Study

Tan et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da74https://doi.org/10.1182/blood-2025-2799
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma2025
  2. 2Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis2025
  3. 3Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies2025 · 11 citations
  4. 4A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma2026 · 1 citations
  5. 5Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses2025